Press Releases

Press Releases

TFF Pharmaceuticals Provides Update on Clinical Development Programs

March 4, 2021

TFF Pharmaceuticals Provides Update on Clinical Development Programs

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2020 Financial Results and Business Results Conference Call on March 10, 2021

February 24, 2021

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2020 Financial Results and Business Results Conference Call on March 10, 2021

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

February 19, 2021

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference

February 12, 2021

TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference

TFF Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

January 7, 2021

TFF Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a Phase 1b Clinical Trial

December 15, 2020

TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a Phase 1b Clinical Trial

TFF Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

November 12, 2020

TFF Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

TFF Pharmaceuticals Reports Third Quarter 2020 Financial and Business Results

November 5, 2020

TFF Pharmaceuticals Reports Third Quarter 2020 Financial and Business Results

TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement

November 5, 2020

TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

November 2, 2020

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

Displaying 21 - 30 of 78
Top